Abstract: Acute myocardial infarction (AMI) remains a major global health burden and is characterized by profound cardiac inflammation, apoptotic cell death, and impaired myocardial function. While interleukin-15 (IL-15) has been implicated in immune regulation, its precise role in the pathogenesis of AMI has not been clarified. Therefore, this study sought to delineate the functional role of IL-15 in the progression of AMI, with a particular focus on its influence on macrophage-driven inflammation, efferocytosis, and metabolic reprogramming. IL-15 levels were assessed in AMI patients and murine models. To evaluate the impact of IL-15 on cardiac inflammation, apoptosis, and functional outcomes following AMI, IL-15 and IL-15 receptor α (IL-15Rα) knockout (KO) mouse models were employed. Mechanistic studies were conducted to investigate IL-15-mediated effects on macrophage efferocytosis, polarization, and metabolic remodeling, with an emphasis on nuclear factor-κB (NF-κB) signaling and glycolytic flux. Elevated IL-15 levels were detected in both the plasma of AMI patients and the cardiac tissues of murine AMI models, correlating with increased disease severity. The genetic deletion of IL-15 or IL-15Rα significantly ameliorated cardiac injury by reducing inflammation and apoptosis while preserving myocardial function. Mechanistic analyses revealed that IL-15 impaired macrophage efferocytosis via Mer tyrosine kinase (MERTK) downregulation and promoted M1 polarization via NF-κB pathway activation. Furthermore, IL-15 reprogrammed macrophage metabolism by enhancing glycolytic activity. Ultimately, IL-15 restoration exacerbated cardiac ischemic injury following AMI, serving as a critical regulator of macrophage-mediated inflammation in AMI. These findings highlight the role of IL-15 as a potential therapeutic and prognostic target for mitigating cardiac inflammation and improving myocardial recovery in AMI.

白介素-15通过损害巨噬细胞胞葬并驱动炎症加重心脏缺血损伤

[1]Allard-ChamardH, MishraHK, NandiM, et al., 2020. Interleukin-15 in autoimmunity. Cytokine, 136:155258.

[2]AmeriK, BayardorjD, SamurkashianR, et al., 2020. Administration of interleukin-15 peptide improves cardiac function in a mouse model of myocardial infarction. J Cardiovasc Pharmacol, 75(1):98-102.

[3]CaiDQ, XaymardanM, HolmJM, et al., 2003. Age-associated impairment in TNF-α cardioprotection from myocardial infarction. Am J Physiol Heart Circ Physiol, 285(2):H463-H469.

[4]ColpittsSL, PuddingtonL, LefrançoisL, 2015. IL-15 receptor α signaling constrains the development of IL-17‒producing γδ T cells. Proc Natl Acad Sci USA, 112(31):9692-9697.

[5]DasekeMJ II, Tenkorang-ImpraimMAA, MaYG, et al., 2020. Exogenous IL-4 shuts off pro-inflammation in neutrophils while stimulating anti-inflammation in macrophages to induce neutrophil phagocytosis following myocardial infarction. J Mol Cell Cardiol, 145:112-121.

[6]DozioE, MalavazosAE, VianelloE, et al., 2014. Interleukin-15 and soluble interleukin-15 receptor α in coronary artery disease patients: association with epicardial fat and indices of adipose tissue distribution. PLoS ONE, 9(3):e90960.

[7]GhaliR, HabeichiNJ, KaplanA, et al., 2020. IL-33 induces type-2-cytokine phenotype but exacerbates cardiac remodeling post-myocardial infarction with eosinophil recruitment, worsened systolic dysfunction, and ventricular wall rupture. Clin Sci, 134(11):1191-1218.

[8]GokkusuC, AydinM, OzkokE, et al., 2010. Influences of genetic variants in interleukin-15 gene and serum interleukin-15 levels on coronary heart disease. Cytokine, 49(1):58-63.

[9]Gómez-NicolaD, Valle-ArgosB, SuardíazM, et al., 2008. Role of IL-15 in spinal cord and sciatic nerve after chronic constriction injury: regulation of macrophage and T-cell infiltration. J Neurochem, 107(6):1741-1752.

[10]HamadaM, NakamuraM, TranMTN, et al., 2014. MafB promotes atherosclerosis by inhibiting foam-cell apoptosis. Nat Commun, 5:3147.

[11]HaoZY, MaJ, DaiJJ, et al., 2020. A real-world analysis of cardiac rupture on incidence, risk factors and in-hospital outcomes in 4190 ST-elevation myocardial infarction patients from 2004 to 2015. Coron Artery Dis, 31(5):424-429.

[12]IrwinMW, MakS, MannDL, et al., 1999. Tissue expression and immunolocalization of tumor necrosis factor-α in postinfarction dysfunctional myocardium. Circulation, 99(11):1492-1498.

[13]JakubzickCV, RandolphGJ, HensonPM, 2017. Monocyte differentiation and antigen-presenting functions. Nat Rev Immunol, 17(6):349-362.

[14]JungM, MaYG, IyerRP, et al., 2017. IL-10 improves cardiac remodeling after myocardial infarction by stimulating M2 macrophage polarization and fibroblast activation. Basic Res Cardiol, 112(3):33.

[15]LambertJM, LopezEF, LindseyML, 2008. Macrophage roles following myocardial infarction. Int J Cardiol, 130(2):147-158.

[16]LiYF, FengLF, LiGR, et al., 2020. Resveratrol prevents ISO-induced myocardial remodeling associated with regulating polarization of macrophages through VEGF-B/AMPK/NF-κB pathway. Int Immunopharmacol, 84:106508.

[17]LiYQ, SunXQ, LiuXN, et al., 2022. P2X7R-NEK7-NLRP3 inflammasome activation: a novel therapeutic pathway of Qishen granule in the treatment of acute myocardial ischemia. J Inflamm Res, 15:5309-5326.

[18]LuanY, YangY, LuanY, et al., 2024. Targeting ferroptosis and ferritinophagy: new targets for cardiovascular diseases. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 25(1):1-22.

[19]McDonaldPP, RussoMP, FerriniS, et al., 1998. Interleukin-15 (IL-15) induces NF-κB activation and IL-8 production in human neutrophils. Blood, 92(12):4828-4835.

[20]MortierE, BernardJ, PletA, et al., 2004. Natural, proteolytic release of a soluble form of human IL-15 receptor α-chain that behaves as a specific, high affinity IL-15 antagonist. J Immunol, 173(3):1681-1688.

[21]MortierE, WooT, AdvinculaR, et al., 2008. IL-15Rα chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med, 205(5):1213-1225.

[22]NgaiD, SchilperoortM, TabasI, 2023. Efferocytosis-induced lactate enables the proliferation of pro-resolving macrophages to mediate tissue repair. Nat Metab, 5(12):2206-2219.

[23]PatidarM, YadavN, DalaiSK, 2016. Interleukin 15: a key cytokine for immunotherapy. Cytokine Growth Factor Rev, 31:49-59.

[24]PereraPY, LichyJH, WaldmannTA, et al., 2012. The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. Microbes Infect, 14(3):247-261.

[25]RidkerPM, EverettBM, ThurenT, et al., 2017. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med, 377(12):1119-1131.

[26]RothGA, MensahGA, JohnsonCO, et al., 2020. Global burden of cardiovascular diseases and risk factors, 1990‒2019: update from the GBD 2019 study. J Am Coll Cardiol, 76(25):2982-3021.

[27]StoneKP, KastinAJ, PanWH, 2011. NFκB is an unexpected major mediator of interleukin-15 signaling in cerebral endothelia. Cell Physiol Biochem, 28(1):115-124.

[28]van den BosscheJ, BaardmanJ, OttoNA, et al., 2016. Mitochondrial dysfunction prevents repolarization of inflammatory macrophages. Cell Rep, 17(3):684-696.

[29]WangYC, ZhengY, QiBC, et al., 2023. α-Lipoic acid alleviates myocardial injury and induces M2b macrophage polarization after myocardial infarction via HMGB1/NF-κB signaling pathway. Int Immunopharmacol, 121:110435.

[30]WeiYZ, LanY, ZhongYC, et al., 2020. Interleukin-38 alleviates cardiac remodelling after myocardial infarction. J Cell Mol Med, 24(1):371-384.

[31]WestmanPC, LipinskiMJ, LugerD, et al., 2016. Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol, 67(17):2050-2060.

[32]WuttgeDM, ErikssonP, SirsjöA, et al., 2001. Expression of interleukin-15 in mouse and human atherosclerotic lesions. Am J Pathol, 159(2):417-423.

[33]XuanWL, HuangWX, WangRJ, et al., 2017. Elevated circulating IL-32 presents a poor prognostic outcome in patients with heart failure after myocardial infarction. Int J Cardiol, 243:367-373.

[34]YanXX, AnzaiA, KatsumataY, et al., 2013. Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction. J Mol Cell Cardiol, 62:24-35.

[35]ZhangYQ, ZhaoJL, LauWB, et al., 2013. Tumor necrosis factor-α and lymphotoxin-α mediate myocardial ischemic injury via TNF receptor 1, but are cardioprotective when activating TNF receptor 2. PLoS ONE, 8(5):e60227.

[36]ZhouSF, YuanJ, LiaoMY, et al., 2014. IL-17A promotes ventricular remodeling after myocardial infarction. J Mol Med, 92(10):1105-1116.

[37]ZouH, ZhangMY, YangX, et al., 2024. Cynaroside regulates the AMPK/SIRT3/Nrf2 pathway to inhibit doxorubicin-induced cardiomyocyte pyroptosis. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 25(9):756-772.

Similar articles